(A) Presence of PD-1, its ligands PD-L1 and PD-L2, and the phosphatases SHP-1, SHP-2, and SHP-2-like (SHP-2L) in representative jawed vertebrates, including sharks, ray-finned fish, amphibians, and ...

A simplified schematic illustrating how cancer cells evade immune attack by expressing PD-L1, which binds to PD-1 on T cells and suppresses their activity. The figure also shows how immune checkpoint ...

Comparative real-world survival of first-line atezolizumab, nivolumab, and pembrolizumab in older patients with metastatic non–small cell lung cancer. This is an ASCO Meeting Abstract from the 2025 ...

Comparison of postoperative adjuvant therapy and surgery alone in pathological N1-2 esophageal squamous cell carcinoma: A prospective multi-center randomized controlled trial. This is an ASCO Meeting ...

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101) of JSKN027, an independently developed ...

SCLC, researchers aimed to determine the consistency of benefit of adding PD-1/PD-L1 inhibitors to platinum-etoposide.

With Bristol Myers Squibb (BMS) now rolling out the SC version of rival nivolumab (Opdivo Qvantig), the shift from 30-minute intravenous (IV) infusion to 5-minute SC injection could be one of the most ...

Durvalumab targets PD-L1, a key immune checkpoint. Normally, antigen-presenting cells (APCs) recognize cancer cell antigens and activate cytotoxic T cells, which travel to the tumor site for ...